Abstract
Tischer and Gergely review the cell biology behind microtubule poisons and their clinical use in cancer patients.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Aurora Kinase A / antagonists & inhibitors
-
Aurora Kinase A / genetics
-
Aurora Kinase A / metabolism
-
Aurora Kinase B / antagonists & inhibitors
-
Aurora Kinase B / genetics
-
Aurora Kinase B / metabolism
-
Cell Cycle Proteins / antagonists & inhibitors
-
Cell Cycle Proteins / genetics
-
Cell Cycle Proteins / metabolism
-
Cell Line, Tumor
-
Clinical Trials as Topic
-
Gene Expression Regulation, Neoplastic / drug effects*
-
Humans
-
Kinesins / antagonists & inhibitors
-
Kinesins / genetics
-
Kinesins / metabolism
-
Microtubules / drug effects*
-
Microtubules / metabolism
-
Mitosis / drug effects*
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / metabolism
-
Neoplasms / pathology
-
Polo-Like Kinase 1
-
Protein Serine-Threonine Kinases / antagonists & inhibitors
-
Protein Serine-Threonine Kinases / genetics
-
Protein Serine-Threonine Kinases / metabolism
-
Proto-Oncogene Proteins / antagonists & inhibitors
-
Proto-Oncogene Proteins / genetics
-
Proto-Oncogene Proteins / metabolism
-
Signal Transduction
-
Tubulin Modulators / therapeutic use*
Substances
-
Antineoplastic Agents
-
Cell Cycle Proteins
-
KIF11 protein, human
-
Proto-Oncogene Proteins
-
Tubulin Modulators
-
AURKA protein, human
-
AURKB protein, human
-
Aurora Kinase A
-
Aurora Kinase B
-
Protein Serine-Threonine Kinases
-
Kinesins